Novoprotein: Its high-throughput wet-lab and data package services that empower AI are still in the early stage of market expansion, with related revenue accounting for less than 2%
Novoprotein announced that its high-throughput wet-lab and data package services that empower AI are still in the early stage of market expansion, and as of the third quarter of 2026, revenue from related businesses accounted for less than 2% of the company's total operating revenue. The company cautioned that the application of AI in the drug R&D industry is still in its infancy, and there are risks such as rapid technological iteration, long industry validation cycles, and significant difficulty in commercial implementation, and future realization of related revenue and profits is subject to major uncertainty. Previously, the company's stock price rose by a cumulative deviation of more than 30% over three consecutive trading days from October 28 to 30, constituting an abnormal fluctuation in stock trading.
Body · AI translation
Novoprotein announced that the company's stock price closed with a cumulative deviation of more than 30% over three consecutive trading days from October 28 to 30, constituting an abnormal fluctuation in stock trading. The company's AI-empowered high-throughput wet lab and data package services are still in the early stage of market expansion, and as of the third quarter of 2026, revenue from the related business accounted for less than 2% of the company's total operating revenue. Given that the application of AI in the pharmaceutical R&D industry is still in its infancy, with risks such as rapid technological iteration, long industry validation cycles, and significant difficulty in commercialization, there is major uncertainty regarding the realization of the company's future related revenue and profits. Investors are advised to view this rationally and be mindful of investment risks.